Tanezumab + Tanezumab + Tanezumab + Tanezumab

Phase 2Terminated

1 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Cystitis, Interstitial

Conditions

Cystitis, Interstitial

Trial Timeline

Jan 22, 2010 → Jan 21, 2011

NCT ID

NCT00999518

About Tanezumab + Tanezumab + Tanezumab + Tanezumab

Tanezumab + Tanezumab + Tanezumab + Tanezumab is a phase 2 stage product being developed by Pfizer for Cystitis, Interstitial. The current trial status is terminated. This product is registered under clinical trial identifier NCT00999518. Target conditions include Cystitis, Interstitial.

What happened to similar drugs?

2 of 5 similar drugs in Cystitis, Interstitial were approved

Approved (2) Terminated (2) Active (2)

✅Pentosan polysulfate sodium 100 mg + Placebo + Pentosan polysulfate sodium 100 mgJohnson & JohnsonApproved

✅RocuroniumMerckApproved

❌Mirabegron + PlaceboAstellas PharmaPhase 3

🔄Certolizumab pegol + PlaceboUCBPhase 3

🔄moxifloxacinBayerPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00999518	Phase 2	Terminated	Jan 22, 2010	Jan 21, 2011	Cystitis, Interstitial
NCT00788294	Phase 1	Completed	Nov 1, 2008	Jun 1, 2009	Healthy Volunteers

Competing Products

19 competing products in Cystitis, Interstitial

See all competitors

Product	Company	Stage	Hype Score
Ferumoxytol + Gadobutrol	Lipella Pharmaceuticals	Phase 1	19
LP-10	Lipella Pharmaceuticals	Phase 2	25
LP-08 80mg + Normal saline + LP-08 20mg	Lipella Pharmaceuticals	Phase 2	25
ASP3652 + Placebo	Astellas Pharma	Phase 2	35
Mirabegron + Placebo	Astellas Pharma	Phase 3	32
ONO-1110 + Placebo	Ono Pharmaceutical	Phase 2	42
Placebo + JNJ-42160443	Johnson & Johnson	Phase 2	27
Pentosan polysulfate sodium 100 mg + Placebo + Pentosan polysulfate sodium 100 mg	Johnson & Johnson	Approved	35
BOTOX + Placebo for BOTOX	AbbVie	Phase 2	35
Rocuronium	Merck	Approved	43
Cidofovir	Gilead Sciences	Pre-clinical	18
PD 0299685 at 15mg BID + PD 0299685 at 30mg BID + placebo for PD 0299685	Pfizer	Phase 2	35
ERB-041	Pfizer	Pre-clinical	18
PF-04383119 + Placebo	Pfizer	Phase 2	35
Certolizumab pegol + Placebo	UCB	Phase 3	40
moxifloxacin	Bayer	Phase 3	37
Cipro (Ciprofloxacin, BAYQ3939)	Bayer	Pre-clinical	23
IW-3300 rectal foam + Placebo	Ironwood Pharmaceuticals	Phase 2	21
MN-001 BID + MN-001 + Placebo	MediciNova	Phase 2	25